Scientific Publications
24Oct, 2018
Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses of Cognitive and Functional Outcomes
Susan Abushakra MD*, Bruno Vellas MD, Serge Gauthier MD, Anton Porsteinsson MD, Carl Sadowsky [...]
3Aug, 2018
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation In Human Brain
John A. Hey, Petr Kocis, Jakub Hort, Susan Abushakra, Aidan Power, Martin Vyhnálek, Jeremy Y. Yu & Martin Tolar
25Jul, 2018
Clinical Benefits of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses from the Phase 3 North American Trial
S. Abushakra, A. Porsteinsson, C. Sadowsky, S. Gauthier, B. Vellas, A. Power, L. [...]
2Nov, 2017
Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease Over 130 Weeks: Results of Phase 3 Extension Study
S. Abushakra, MD, A. Porsteinsson, MD, C. Sadowsky, MD, B. Vellas, MD, S. [...]
23Oct, 2017
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
John A. Hey, Jeremy Y. Yu, Mark Versavel, Susan Abushakra, Petr Kocis, Aidan [...]
17Jul, 2017
ALZ-801 Mechanism of Action: Stoichiometry of Beta Amyloid Anti-Oligomer Effect, PK/PD, and Clinical Dose Selection for Confirmatory Phase 3 Program in Alzheimer’s Disease
J.A. Hey, P. Kocis, S. Abushakra, J. Yu , A. Power, K. Blennow, [...]